Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1899-1902

  Beattie, Gerald J ^a   Smyth, John F ^b  

^a ST JOHN'S HOSPITAL   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MALIGNANT NEOPLASTIC DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASMS; PHENYLALANINE; PROTEASE INHIBITORS; THIOPHENES;

EID: 0031848158     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Ward, R. V., Atkinson, S. J., Slocombe, P. M., Docherty, A. J. P., Reynolds, J. J., and Murphy, G. Tissue inhibitor of metalloproteinase-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim. Biophys. Acta, 1079: 242-246, 1991.
2. Collier, I. E., Wilhelm, S. M., Eisen, A. Z., Marmer, B. L., Grant, G. A., Seltzer, J. L., Kronberger, A., He, C., Bauer, E. A., and Goldberg, G. I. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J. Biol. Chem., 263: 6579-6587, 1988.
3. Chin, J. R., Murphy, G., and Werb, Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblast in parallel with collagenase. J. Biol. Chem., 260: 12367-12376, 1985.
4. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. A matrix d metalloproteinase expressed on the surface of invasive tumour cells. Nature (Lond.), 370: 61-65, 1994.
5. Reponen, P., Sahlberg, C., Huhtala, P., Hurskainen, T., Thesleff, I., and Tryggvason, K. Molecular cloning of murine 72-kDa type IV collagenase and its expression during mouse development. J. Biol. Chem., 267: 7856-7862, 1992.
6. Agren, M. S., Taplin, C. J., Woessner, J. F., Eaglestein, W. H., and Mertz, P. M. Collagenase activity during wound-healing. J. Invest. Dermatol., 98: 621, 1992.
7. Okada, Y., Nagase, H., and Harris, E. G., Jr. Matrix metalloproteinase 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. J. Rheumatol., 14: 41-42, 1987.
8. Alvarex, O. A., Carmichael, D. F., and DeClerck, Y. A. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst., 82: 589-595, 1990.
9. Davies, B., Brown, P. D., East, N., Crimmin, M. J., and Balkwill, F. R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian cancer xenografts. Cancer Res., 53: 2087-2091, 1993.